Redeye is bullish about the new results with BI-1808 in cutaneous T-cell lymphoma. The path towards a market approval for BI-1808 is beginning to look clearer. The BI-1206 data are also interesting but more difficult to interpret at this early stage of the trial.
LÄS MER
